Results 91 to 100 of about 87,055 (280)

COVID-19 Presentation in Association with Myasthenia Gravis: A Case Report and Review of the Literature

Case Reports in Infectious Diseases, 2020
Currently, there are scarce data on how COVID-19 affects people with myasthenia gravis. Theoretically, there is a higher risk of experiencing severe manifestations of COVID-19 due to the common use of immunosuppressive drugs and potential respiratory ...
E. Aksoy, T. Oztutgan
semanticscholar   +1 more source

Switching Enzyme Replacement Therapy for Late‐Onset Pompe Disease From Alglucosidase Alfa to Cipaglucosidase Alfa Plus Miglustat: Post Hoc Effect Size Analysis of PROPEL

Muscle &Nerve, EarlyView.
A total of 95 ERT‐experienced adults with LOPD were randomized to switch to cipaglucosidase alfa + miglustat or remain on alglucosidase alfa treatment. After 52 weeks, patients remaining on alglucosidase alfa showed worsening or stability for most outcomes, whereas patients who switched to cipaglucosidase alfa + miglustat generally showed stability or ...
Hani Kushlaf, Jordi Díaz‐Manera, Drago Bratkovic, Barry J. Byrne, Kristl G. Claeys, Paula R. Clemens, Mazen M. Dimachkie, Priya S. Kishnani, Pascal Laforêt, Mark Roberts, Benedikt Schoser, Antonio Toscano, Jeff Castelli, Fred Holdbrook, Sheela Sitaraman Das, Mitchell Goldman, Tahseen Mozaffar, on behalf of the PROPEL Study Group   +17 more
wiley   +1 more source

Coexistence of Pernicious Anemia and Myasthenia Gravis—A Rare Combination of Autoimmune Diseases in Taiwan

Journal of the Formosan Medical Association, 2006
About 5-10% of patients with myasthenia gravis concomitantly have other autoimmune diseases. However, the coexistence of myasthenia gravis and pernicious anemia is rare.
Kuo-Hsuan Chang, Rong-Kuo Lyu, Long-Sun Ro, Yih-Ru Wu, Chiung-Mei Chen   +4 more
doaj   +1 more source

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Neurology and Therapy, 2023
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N. Beasley, Nishi Rampal, James F. Howard   +9 more
doaj   +1 more source

Mycophenolate Facilitates Improvement in Outcome Measures in Treatment Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a potentially disabling autoimmune neuropathy. Approximately 20% of patients are refractory to first‐line treatments necessitating second‐line options with limited evidence and potential adverse effects.
Shamim Miah, Nicole Japzon, Amar Elsaddig, Shiwen Koay, Laura Compton, Michael P. Lunn, Aisling S. Carr   +6 more
wiley   +1 more source

Measuring Adverse Event Burden in Myasthenia Gravis: Retrospective Validation of the Adverse Event Unit With Randomized Trial of Thymectomy in Myasthenia Gravis Data

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims The Adverse Event Unit (AEU) is a patient and physician weighted unit that quantifies and compares adverse event (AE) burden among any neurologic treatments. A recent study demonstrated feasibility and preliminary validity of the AEU in myasthenia gravis (MG).
Michael K. Hehir, Inmaculada B. Aban, Henry J. Kaminski   +2 more
wiley   +1 more source

Dental Care in Patients with Myasthenia Gravis

Česká Stomatologie a Praktické Zubní Lékařství, 2010
Myasthenia gravis is an autoimmune disease in the neuromuscular transmission, causing muscular weakness and fatique especially in the facial and pharyngeal muscles.
J. Piťha
doaj  

MGBase: A Global, Observational Registry for Collaborative Research in Myasthenia Gravis

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Patient registries are valuable tools for outcomes research in rare diseases such as myasthenia gravis (MG). Existing MG registries are limited by factors including a lack of geographical scope. MGBase has been designed as a global, observational registry aimed at studying clinical practice outcomes in MG.
Katherine A. Buzzard, Anneke Van der Walt, Helmut Butzkueven, Wen Wen Zhang, Carolina Barnett‐Tapia, Gary Cutter, Jeannine M. Heckmann, Pamela Farr, Carolyn Tran, Charlotte Sartori, Dusko Stupar, Rein More, Linda Sim, Alison Le, Qingxiao Tang, Stephen W. Reddel, the MGBase Study Group, Stefan Blum, Gabvor Lovas, Pamela McCombe, Elisabeth Chroni, Belinda Cruse, Raed Alroughani, John Tzartos, Enrique Gomex‐Figueroa, Cavit Boz, Guntis Karelis, Allan Kermode, Nicholas Crump   +28 more
wiley   +1 more source

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

Muscle and Nerve, 2019
Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody‐positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open‐label extension of REGAIN,
S. Muppidi, K. Utsugisawa, M. Benatar, H. Murai, R. Barohn, I. Illa, S. Jacob, J. Vissing, T. Burns, J. Kissel, R. Nowak, H. Andersen, C. Casasnovas, J. D. De Bleecker, T. Vu, R. Mantegazza, F. O'Brien, Jing Jing Wang, K. Fujita, J. Howard   +19 more
semanticscholar   +1 more source

Breathing and balance: Clinical insights and management strategies of respiratory acid‐base disorders

Nutrition in Clinical Practice, EarlyView.
Abstract Respiratory acidosis and alkalosis are two of the four main acid‐base processes encountered in clinical practice. These two processes are tightly balanced by breathing. Identification and management of respiratory acid‐base disorders are important for clinicians, particularly when caring for patients with underlying pulmonary and neurological ...
Anne M. Tucker, Tami N. Johnson
wiley   +1 more source